GLP 1 RA
Reading Document
Medical Text Search
GLP-1 receptor agonists mechanism of action pharmacology
Medical Text Search
GLP-1 RA clinical uses diabetes obesity cardiovascular outcomes
GradeResponse
GradeResponse
Medical Text Search
GLP-1 receptor agonist drugs comparison semaglutide liraglutide dulaglutide exenatide dosing
Medical Text Search
GLP-1 RA side effects adverse effects nausea vomiting contraindications
GLP-1 Receptor Agonists (GLP-1 RAs)
Mechanism of Action
GLP-1 (glucagon-like peptide-1) is a naturally secreted incretin polypeptide. GLP-1 RAs mimic or enhance its activity at GLP-1 receptors expressed across multiple organs:
| Organ | Effect |
|---|---|
| Pancreas | Glucose-dependent insulin secretion ↑, glucagon ↓ |
| Brain | Satiety ↑, appetite ↓ (hypothalamic signaling) |
| Stomach | Gastric emptying slowed ("ileal brake") |
| Heart | Cardioprotective effects (reduced MACE) |
| Kidney | Natriuresis, reduced proteinuria |
Because insulin secretion is glucose-dependent, hypoglycemia risk is low as monotherapy.
Available Agents
| Drug | Brand | Route | Frequency | Half-life |
|---|---|---|---|---|
| Semaglutide | Ozempic / Wegovy / Rybelsus | SC / Oral | Weekly / Daily | ~7 days |
| Liraglutide | Victoza / Saxenda | SC | Daily | ~13 hrs |
| Dulaglutide | Trulicity | SC | Weekly | ~5 days |
| Exenatide | Byetta / Bydureon | SC | BID / Weekly | ~2.4 hrs / ~2 weeks |
| Albiglutide | Tanzeum | SC | Weekly | ~5 days |
| Lixisenatide | Adlyxin | SC | Daily | ~3 hrs |
| Efpeglenatide | Investigational | SC | Weekly | ~10 days |
Clinical Indications
1. Type 2 Diabetes Mellitus
- Reduce HbA1c (typically 1–2%)
- ADA/EASD guidelines favor GLP-1 RAs in patients with established ASCVD, HF, or CKD due to cardiorenal benefits
- Can be combined with metformin, SGLT2 inhibitors, or insulin
2. Obesity / Weight Management
- Semaglutide 2.4 mg SC weekly (Wegovy) and liraglutide 3 mg SC daily (Saxenda) are FDA-approved for chronic weight management
- Semaglutide trials (STEP program) showed ~15–17% body weight reduction
3. Cardiovascular Risk Reduction
Five GLP-1 RAs have demonstrated significant MACE reduction in major CVOTs (per ADA CKD guidelines):
- Liraglutide — LEADER trial
- Semaglutide — SUSTAIN-6 trial
- Albiglutide — HARMONY trial
- Dulaglutide — REWIND trial
- Efpeglenatide — AMPLITUDE-O trial
Lixisenatide, exenatide, and oral semaglutide demonstrated cardiovascular safety but not significant MACE reduction.
4. CKD / Cardiorenal Protection
- Shown to reduce albuminuria and slow CKD progression
- Preferred in T2DM + CKD patients alongside SGLT2 inhibitors
Side Effects
| Category | Effects |
|---|---|
| GI (most common) | Nausea, vomiting, diarrhea, constipation (dose-dependent, usually transient) |
| Injection site | Reactions with SC formulations |
| Delayed gastric emptying | Relevant for perioperative management (aspiration risk) |
| Pancreatitis | Rare; discontinue if suspected |
| Thyroid C-cell tumors | Seen in rodent models; black box warning for MTC and MEN2 |
| Gallbladder | Cholelithiasis, cholecystitis (especially with rapid weight loss) |
| Hypoglycemia | Rare as monotherapy; higher risk combined with insulin/sulfonylureas |
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- MEN type 2
- Pregnancy (discontinue at least 2 months before conception for semaglutide)
- Severe GI disease (gastroparesis — use with caution)
Perioperative Considerations
GLP-1 RAs slow gastric emptying, increasing aspiration risk. Per current guidance:
- Short-acting agents (daily): hold on day of procedure
- Weekly agents: hold 1 week prior to elective procedures requiring anesthesia
- Extended fasting or gastric ultrasound may be warranted if not held
Key Comparisons: GLP-1 RA vs. SGLT2 Inhibitors
| Feature | GLP-1 RA | SGLT2i |
|---|---|---|
| Weight loss | +++ | ++ |
| HbA1c reduction | ++ | ++ |
| CV benefit (ASCVD) | +++ | +++ |
| HF benefit | + | +++ |
| CKD protection | ++ | +++ |
| Hypoglycemia risk | Low | Low |
| Route | SC / Oral | Oral |
Summary
GLP-1 RAs are a cornerstone of modern metabolic medicine, offering glucose lowering, significant weight reduction, and proven cardiovascular and renal protection. Semaglutide (weekly SC or oral) currently leads in efficacy for both T2DM and obesity. The GI side effect profile is the main tolerability challenge; titrating doses slowly mitigates this.
Sources: Safe Use of GLP-1 RAs in the Perioperative Period (p. 1); Diabetes Management in Chronic Kidney Disease (p. 83, ADA/KDIGO guidelines)
This is a shared conversation. Sign in to Orris to start your own chat.